Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs
- Bias Rating
-22% Somewhat Liberal
- Reliability
45% ReliableFair
- Policy Leaning
-28% Somewhat Liberal
- Politician Portrayal
6% Positive
Continue For Free
Create your free account to see the in-depth bias analytics and more.
Continue
Continue
By creating an account, you agree to our Terms and Privacy Policy, and subscribe to email updates. Already a member: Log inBias Score Analysis
The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.
Sentiments
15% Positive
- Liberal
| Sentence | Sentiment | Bias |
|---|---|---|
Unlock this feature by upgrading to the Pro plan. | ||
Reliability Score Analysis
Policy Leaning Analysis
Politician Portrayal Analysis
Bias Meter
Extremely
Liberal
Very
Liberal
Moderately
Liberal
Somewhat Liberal
Center
Somewhat Conservative
Moderately
Conservative
Very
Conservative
Extremely
Conservative
-100%
Liberal
100%
Conservative
Contributing sentiments towards policy:
63% : Eli Lilly (LLY) and Novo Nordisk (NVO) shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' popular weight-loss drugs in government-backed healthcare plans including Medicare and Medicaid.54% : Over a 10-year period, the Centers for Medicaid and Medicare Services (CMS) estimates that the change would cost $24.8 billion for Medicare and $14.8 billion for Medicaid.
*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.